Elevated Serum IL-17A but not IL-6 in Glioma Versus Meningioma and Schwannoma

• DOI: 10.7314/apjcp.2013.14.9.5225
• Publication Date: 2014-03-21T01:41:06Z
• Authors: Mehrnoosh Doroudchi; Zahra Ghanaat Pishe; Mahyar Malekzadeh; Hossein Golmoghaddam; Mousa Taghipour; Abbas Ghaderi
• Keywords: Adult; Aged, 80 and over; Male; Adolescent; Brain Neoplasms; Interleukin-6; Interleukin-17; Glioma; Middle Aged; Th1 Cells; 03 medical and health sciences; 0302 clinical medicine; Case-Control Studies; Child, Preschool; Biomarkers, Tumor; Meningeal Neoplasms; Humans; Female; Child; Meningioma; Neurilemmoma; Aged

There is a Th1/Th2 cytokine imbalance and expression of IL-17 in patients with brain tumours. We aimed to compare the levels IL-17A IL-6 sera glioma, meningioma schwannoma as well healthy individuals.IL-17A were measured 38 24 18 for comparison 26 controls by commercial ELISA assays.We observed an increase 30% glioma while only 4% 5.5% none showed elevated their (0.29 ± 0.54, 0.03 0.15 0.16 0.68 vs. 0.00 pg/ml; p=0.01, p=0.01 p=0.001, respectively). was also significant decrease level compared (2.34 4.35 4.67 4.32 p=0.01). direct correlation between age (p=0.005). Glioma over 30 years had higher lower young patients. In addition, non-significant grade-specific inverse trend patients, where high-grade gliomas IL-6.Our data suggest Th17 mediated inflammatory response pathogenesis glioma. Moreover, tuning cytokines occurs during progression may be potential biomarker and/or immunotherapeutic target cases.